Searchable abstracts of presentations at key conferences in endocrinology

ea0020p88 | Thyroid | ECE2009

What is the outcome of combined therapies in amiodarone-induced thyrotoxicosis?

Trifanescu Raluca-Alexandra , Ursu Horea , Purice Mariana

Objective: To assess the outcome of medical and ablative therapies in amiodarone-induced thyrotoxicosis (AIT).Subjects and methods: Seventy patients (32 M/38 F, aged 59.7±1.4 years) with AIT (24-type 1, 20-type 2 and 26-mixed forms) were followed-up 13.4±2.3 months. TSH was measured by immunoradiometric assay, TT3 and TT4 by chemiluminescence.Results: Antithyroid drugs (ATD) were used as single thera...

ea0016p284 | Endocrine tumours | ECE2008

Correlation between postoperative hypothyroidism and seric homocysteine at the patients with thyroid carcinoma

Goldstein Andrei Liviu , Alexiu Florin , Purice Mariana

Carcinoma of the thyroid gland is an uncommon cancer but is the most common malignancy of the endocrine system. The treatment of the thyroid cancer includes surgery, radioactive iodine and hormone treatment. Postoperative hypothyroidism is the most common complication of thyroidectomy for thyroid cancer. After thyroidectomy, the patient takes a thyroid hormone drug (levothyroxine) in supresive dose for the rest of his life.In hypothyroidism there has bee...

ea0032p892 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Measurement of hGH in acromegalic patients under pegvisomant treatment

Purice Mariana , Gheorghiu Monica , Jercalau Simona , Badiu Corin

Generously supported by IPSEN)-->Treatment with hormone analogues can challenge the precise measurement by interference with the routinely used immunoassays systems, related to the presence of autoantibodies in the serum, interference with associated therapy or the presence of altered forms of the hormone, with modified biological activity and/or immunoreactivity.In patients with acromegaly treated with the hGH...

ea0020oc4.2 | Acromegaly/IGF1/Type 2 Diabetes | ECE2009

Both insulin resistance and insulin secretion are involved in the pre-diabetes of acromegaly

Niculescu Dan , Purice Mariana , Lichiardopol Radu , Coculescu Mihail

In acromegalic patients growth hormone (GH) excess induces insulin resistance but whether this is sufficient, in the face of normal insulin secretion, for pre-diabetes (impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)) to occur is a matter of debate.Aim: To assess the relative role of insulin resistance and insulin secretion in the pre-diabetes of acromegaly.Methods: One hundred and twenty-four patients with acro...

ea0020p224 | Endocrine tumours and neoplasia | ECE2009

Lanreotide effects on glucose metabolism in evolutive acromegaly in remission during chemotherapy

Galoiu Simona , Purice Mariana , Hortopan Dan , Dumitrascu Anda , Coculescu Mihail

Lanreotide has long been used in the therapy of GH secreting pituitary adenomas and other somatostatin receptor positive neuroendocrine tumors.Aims: To determine the impact on glucose metabolism of the 6 months of lanreotide therapy, beside of the antisecretory and antiproliferative effects.Patients and methods: Seven patients with active acromegaly treated with lanreotide, admitted in the Department of Neuroendocrinology, Institut...

ea0014p83 | (1) | ECE2007

Insulin resistance and insulin secretion in non-diabetic acromegalic patients

Niculescu Dan , Purice Mariana , Lichiardopol Radu , Coculescu Mihail

Aim: To set up, in acromegaly without diabetes mellitus, a correlation between the disease activity in GH-secreting adenoma (AA) - assessed by minimum GH serum level during an oral glucose tolerance test (OGTT) - and severity of insulin resistance (IR), assessed by HOMA-IR index.Methods: 75 out of 88 consecutive patients with acromegaly hospitalized in our department were included in this study. 13 patients proved to have diabetes mellitus and were exclu...

ea0049ep1353 | Thyroid (non-cancer) | ECE2017

Pattern of amiodarone-induced thyrotoxicoxis before and after universal salt iodization

Trifanescu Raluca , Popa Cristina , Goldstein Andrei , Alexiu Florin , Purice Mariana , Poiana Catalina

Background: Prevalence and type of amiodarone-induced thyroid dysfunction in a population depend on geographical iodine intake.Aims: To assess differences in amiodarone-induced thyrotoxicosis pattern before and after iodine supplementation.Patients and methods: 84 patients (41M/43F) with amiodarone-induced thyrotoxicosis, aged 60.1±11.9 years, were retrospectively reviewed. 28 patients were resident in former iodine-deficient ...

ea0037ep757 | Pituitary: clinical | ECE2015

Cure rates and survival in patients with acromegaly

Galoiu Simona , Suvoiala Andreea , Purice Mariana , Caragheorgheopol Andra , Trifanescu Raluca , Coculescu Mihail , Poiana Catalina

Introduction: An improvement of survival in patients with acromegaly was claimed in the last years, with multimodal new therapies.Aims: To assess cure rates of different therapeutic protocols and the impact of these therapies on survival.Methods: 334 patients (224 F/110 M, mean age 48.1±0.7 years) with acromegaly admitted in a single Neuroendocrinology Department between Jan 2001 and Dec 2013 were retrospectively studied by GH...

ea0037ep1144 | Endocrine tumours | ECE2015

Differentiated thyroid carcinoma arising from or associated with struma ovarii: a report of two cases

Vija Lavinia , Goldstein Andrei , Neamtu Daniela , Purice Mariana , Alexiu Florin , Piciu Doina , Badiu Corin

Introduction: Struma ovarii is a rare condition which elicited considerable interest because of its many unique features like its relationship to teratoma and differentiated thyroid cancer. The most common thyroid carcinomas to arise in struma ovarii are papillary and follicular.Objectives: We describe two patients with differentiated thyroid carcinoma originating from malignant struma ovarii.Results: Our index patient is a 32-year...

ea0070aep580 | Pituitary and Neuroendocrinology | ECE2020

Real life efficiency of pegvisomant therapy in acromegaly

Maria Lider Burciulescu Sofia , Livia Gheorghiu Monica , Caragheorgheopol Andra , Purice Mariana , Badiu Corin

Introduction: Pegvisomant (PEG) is an efficient treatment for acromegaly but the recommendation for this treatment is less active due to its high cost. In Romania it is reimbursed in doses up to 30 mg s.c/day or as 40 or 80 mg/week in combination with a somatostatin analog (SSA).Design: Retrospective analysis of 18 consecutive patients treated with PEG for acromegaly (either as monotherapy, or in combination with SSA and/or cabergoline (CAB...